MBX Biosciences, Inc.
MBX· Nasdaq
Released Aug 6, 2026, before the open
10-Q filed Aug 6, 2026, 37 days after period end · 0001193125-26-336849
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$37.10M | -$19.41M | -$15.86M | -$7.61M |
| EPS Diluted | -$0.78 | -$0.58 | -$12.62 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MBX Biosciences, Inc. · CIK 1776111 · Engraved from SEC EDGAR